Evidence map›Paper›PMID 40075013›Full record

ReviewMedical oncology (Northwood, London, England)2025

Exosomal RNAs and EZH2: unraveling the molecular dialogue driving tumor progression.

Ahmed Hussein Zwamel, Abdulrahman T Ahmad, Farag M A Altalbawy, H Malathi, Amandeep Singh, Majid S Jabir, Zafar Aminov, Madan Lal, Abhinav Kumar, Sabrean F Jawad

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmed Hussein ZwamelMedical Laboratory Technique College, The Islamic University, Najaf, Iraq.
Abdulrahman T AhmadCollege of Nursing, University of Al Maarif, Ramadi, Al-Anbar, Iraq. Abdulrahman.dheyab@uoa.edu.iq.
Farag M A AltalbawyDepartment of Chemistry, University College of Duba, University of Tabuk, Tabuk, Saudi Arabia. altalbawyf@gmail.com.ORCID https://orcid.org/0000-0003-2708-9159
H MalathiDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to Be University), Bengaluru, Karnataka, India.
Amandeep SinghChandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali, 140307, Punjab, India.
Majid S JabirDepartment of Applied Sciences, University of Technology, Baghdad, Iraq.
Zafar AminovDepartment of Public Health and Healthcare Management, Samarkand State Medical University, Samarkand, Uzbekistan.
Madan LalDepartment of Medicine, National Institute of Medical Sciences, NIMS University, Rajasthan, Jaipur, India.
Abhinav KumarDepartment of Nuclear and Renewable Energy, Ural Federal University Named after the First President of Russia Boris Yeltsin, Ekaterinburg 620002, Russia.
Sabrean F JawadDepartment of Pharmacy, Al-Mustaqbal University College, Babylon, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The EZH2 gene encodes an enzyme that is part of the epigenetic factor Polycomb Repressive Complex 2 (PRC2). In order to control gene expression, PRC2 mainly modifies chromatin structure. In this complex process, EZH2 methylates histone proteins, which in turn suppresses further RNA transcriptions. As a result, EZH2 dysregulations can occasionally induce abnormal gene expression patterns, which can aid in the development and progression of cancer. Non-coding RNAs significantly impact the expression of EZH2 through epigenetic mechanisms. Meanwhile, normal and cancerous cells frequently release vesicles into the extracellular matrix, also known as exosomes, that occasionally carry RNA molecules from their origin cells, including messenger RNAs, microRNAs, and other non-coding RNAs. Thus exosomes are granted the ability to regulate numerous physiological functions and act as crucial messengers between cells by influencing gene expression in the recipient cell. We conducted this review to focus on EZH2's substantial biological role and the mechanisms that regulate it, driven by the desire to understand the possible impact of exosomal RNAs on EZH2 expression.

Indexed as

Enhancer of Zeste Homolog 2 ProteinExosomesNeoplasmsAnimalsDisease ProgressionEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansMicroRNAsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMicroRNAsExosomesEZH2NeoplasmRNA

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.